Compositions comprising intermediate non-coding RNA regulators to modulate expression of ETV6 or FOXO1 and uses thereof
Patent Information
- Application Number
- JP2024076795
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-07-27
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-01
AI Technical Summary
Current technologies fail to effectively address the dysregulation of splicing factors and cellular senescence, which contribute to age-related diseases and cancer, by targeting upstream drivers of age-related splicing dysregulation.
Compositions comprising intermediate non-coding RNA regulators, such as miRNAs, are developed to modulate the expression of FOXO1 and/or ETV6, thereby attenuating their gene expression and reducing cellular senescence and cell cycle re-entry.
These compositions successfully reverse senescence and re-enter the cell cycle, offering therapeutic potential for age-related diseases and cancer by targeting splicing factor expression and cellular senescence.
Abstract
Description
[Technical field]
[0001] The present invention relates to compositions that modulate the expression of FOXO1 and / or ETV6 or their targets involved in the regulation of splicing factors. Such compositions have therapeutic potential in the prevention, management, amelioration or treatment of age-related diseases or conditions, or cancer, and as research tools / reagents. [Background technology]
[0002] Senescent cells are viable, metabolically active entities that have lost the ability to proliferate through multiple rounds of cell division and have been shown to accumulate during the aging process in multiple tissues and multiple species (Faragher et al., 2017). Senescent cells release a cocktail of proinflammatory cytokines and remodeling proteins, termed senescence-associated secretory phenomena (SASP), which act in a paracrine manner to induce the establishment of senescence in neighboring cells and further stimulate inflammation in the surrounding tissues (Salama et al., 2014). A large body of evidence suggests that an increase in senescent cell burden directly contributes to organismal aging (de Magalhaes, 2004) and age-related diseases (van Deursen, 2014), and targeted depletion of senescent cells in transgenic mice ameliorates multiple aging phenotypes and extends lifespan (Baker et al., 2016; Baar et al., 2017). Therefore, understanding the basic biology of cellular senescence, and importantly, the factors that contribute to cellular senescence, is of enormous importance.
[0003] One area that is emerging as a potential driver of cellular senescence and aging phenotypes is the dysregulation of alternative splicing (Deschenes and Chabot, 2017; Latorre and Harries, 2017). Fine control of gene expression is essential for controlling cell function, plasticity, and cell identity. Altered expression of regulatory mechanisms governing splice site selection has been found in aging human populations (Harries et al., 2011), in senescent cells of multiple lineages (Holly et al., 2013), and has also been associated with longevity in animal models (Heintz et al., 2016; Lee et al., 2016). Age-related diseases such as Alzheimer's, Parkinson's or cancer are also characterized by large-scale dysregulation of splicing, highlighting the importance of correct splicing for health throughout the life course (Latorre and Harries, 2017). Splicing factors are good candidates for target genes that influence cellular senescence. Because some splicing factors are closely associated with the control of proliferation, and some are involved in maintaining telomere function (Kang et al., 2009; Anczukow et al., 2012), loss of control of alternative splicing in aging tissues may therefore underpin the exacerbated response to intrinsic and extrinsic cellular stressors that characterize aging in multiple species (Kourtis and Tavernarakis, 2011) and may contribute significantly to increased physiological frailty.
[0004] The upstream drivers of age-related splicing dysregulation remain to be elucidated. Genes encoding splicing factors are themselves controlled by alternative splicing, which, of course, represents a strong contribution to their expression (Lareau and Brenner, 2015). It is also known that the control of splicing factor activity at the protein level is determined by the action of SRPK protein kinases and by PI3K / PTEN / AKT signaling at the level of phosphorylation and subcellular localization (Blaustein et al., 2005; Bullock and Oltean, 2017). Previous studies have suggested that some splicing factors may be controlled by alterations in RAF / MEK / ERK signaling (Tarn, 2007). The concept of dysregulation of cell signaling during aging is not new. The role of insulin / insulin-like growth factor 1 (IGF1 / INS) signaling in aging is well known and is the first molecular pathway associated with aging (Cohen and Dillin, 2008). Mutations in many genes within this pathway have been shown to extend lifespan (Suh et al., 2008). Manipulation of the IGF-1 / INS pathway by genetic modification or dietary restriction has also demonstrated the importance of these pathways in human lifespan extension (van Heemst et al., 2005) and has been linked to longevity in model systems (Slack et al., 2015). RAF / MEK / ERK and PI3K / PTEN / AKT signaling intersect immediately downstream of IGF-1 / INS signaling and are also activated by classical "aging" stimuli such as DNA damage, dysregulated growth factors and inflammation (Fontana et al., 2012; Lin et al., 2013).
[0005] Some studies suggest that the use of MEK or PI3K inhibitors can prevent the induction of cellular senescence and aging (Demidenko et al., 2009; Chappell et al., 2011). The NFκB pathway controls the cellular senescence-associated secretory phenomenon (SASP) (Salminen et al., 2012), but this NFκB pathway is also known to intersect with ERK and AKT signaling (Lin et al., 2012), suggesting that inflammatory changes can exist both upstream and downstream of RAF / MEK / ERK signaling. However, the relationship between these pathways is not simple. There is crosstalk between them, as well as dosage, cell type and context effects (Rhim et al., 2016). Therefore, activation of ERK and AKT signaling by classical senescence stimuli such as DNA damage, inflammation or growth factors may induce dysregulation of splicing factor expression and alternative splicing, affecting cellular senescence. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Faragher RG et al., F1000Res. 6, 1219(2017) [Non-Patent Document 2] Salama R et al., Genes Dev. 28, 99-114 (2014) [Non-Patent Document 3] de Magalhaes JP, Exp Cell Res. 300, 1-10 (2004) [Non-Patent Document 4] van Deursen JM, Nature. 509, 439-446(2014) [Non-Patent Document 5] Baker DJ et al., Nature. 530, 184-189 (2016) [Non-Patent Document 6] Baar M et al., Cell 169, 133-147(2017) [Non-Patent Document 7] Deschenes MおよびChabot B、Aging Cell(2017) [Non-licensed document 8] Latorre EおよびHarries LW, Ageing Res Rev. 36, 165-170(2017)
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Non-licensed Document 12
Non-licensed Document 13
Non-licensed Document 14
Non-licensed Document 15
Non-licensed Document 16
Non-licensed Document 17
Non-licensed Document 18
Non-licensed Document 19
[0007] It is an object of the present invention to provide compositions having one or more of the following functions: attenuating gene expression of FOXO1 and / or ETV6, regulating expression of splicing factors, or reducing or reversing cellular senescence and / or cell cycle re-entry. Ideally, such compositions may be used as therapeutic agents targeting age-related diseases or conditions, or cancer. [Means for solving the problem]
[0008] According to one aspect of the present invention, there is provided a composition comprising one or more intermediate non-coding RNA regulatory factors that regulate the expression of ETV6 for use in the prevention, management, amelioration or treatment of an age-related disease or condition or cancer.
[0009] The age-related disease or condition or cancer may involve dysregulation of expression of splicing factors and / or dysregulation of cellular senescence.
[0010] According to a further aspect of the present invention there is provided a composition comprising one or more intermediate non-coding RNA regulatory factors that regulate expression of FOXO1 for use in the prevention, management, amelioration or treatment of an age-related disease or condition or cancer, wherein the age-related disease or condition or cancer comprises dysregulation of splicing factor expression and / or dysregulation of cellular senescence.
[0011] According to yet a further aspect of the present invention there is provided a composition for modulating expression of FOXO1 and / or ETV6, the composition comprising one or more intermediate non-coding RNA regulatory factors.
[0012] According to another aspect of the present invention, there is provided a composition for attenuating expression of a splicing factor, the composition comprising an expression regulator of FOXO1 and / or ETV6 or their downstream targets involved in regulating splicing factors.
[0013] According to yet a further aspect of the present invention there is provided a composition for reducing or reversing cellular senescence and / or re-entry into the cell cycle comprising an expression regulator of FOXO1 and / or ETV6 or their downstream targets associated with regulation of splicing factors.
[0014] It will be apparent to one of skill in the art that the compositions of the above embodiments may comprise separate modulators of FOXO1 and ETV6, or their individual or combined target genes. Alternatively, the compositions may simply comprise a combined modulator of FOXO1 and ETV6, or their target genes.
[0015] The inventors advantageously found that modulating the expression of FOXO1 and / or ETV6 targets the activity of downstream effectors of splicing and senescence and may therefore represent promising targets for a range of future therapeutic approaches.
[0016] The regulation of FOXO1 and / or ETV6 or their target genes in the above embodiments can be achieved by using several types of molecules, such as inhibitors. An inhibitor is any molecule or molecules that limits, prevents or blocks the action or function of FOXO1 and / or ETV6, or any downstream effector molecule.
[0017] The regulator of FOXO1 and / or ETV6 expression may include one or more intermediate non-coding RNA regulators. The one or more intermediate non-coding RNA regulators may include two or more intermediate non-coding RNA regulators.
[0018] The intermediate non-coding RNA regulator may comprise miRNA, miRNA mimic, or antagomiR. In certain embodiments, the intermediate non-coding RNA regulator is selected from one or more of the following: MIR142; MIR3124; MIR3188; MIR3196; MIR320E; MIR330; MIR3675; MIR4316; MIR4488; MIR4496; MIR4513; MIR4674; MIR4707; MIR4772; MIR6088; MIR6129; MIR6780A; MIR6797; MIR6803; MIR6810; MIR6842; or MIR7155. More preferably, the intermediate non-coding RNA regulatory element is selected from one or more of the following: MIR3124; MIR3675; MIR4496; MIR6780A; MIR6810; MIR6842; or MIR7155.
[0019] Biochemical and functional pathways enriched in target genes of FOXO1 or ETV6 are illustrated below in Table A. Potentially, disruption of any one of the genes or pathways outlined in Table A could result in modulation of expression of FOXO1 and / or ETV6.
[0020] [Table 1]
[0021] Cellular plasticity is a key factor of cellular homeostasis that requires correct temporal and spatial patterns of alternative splicing. Splicing factors that orchestrate this process show age-related expression abnormalities and have emerged as potential factors that influence aging and longevity. The upstream drivers of these changes remain to be defined but may involve aberrant intracellular signaling.
[0022] We compared the phosphorylation status of proteins in multiple signaling pathways in early and late passage human primary fibroblasts and determined the response of "young" cells to cytokines known to be activators of ERK and AKT signaling. We then assessed the effects of chemical inhibition, or targeted knockdown, of direct downstream targets of the ERK and AKT pathways on splicing factor expression, cellular senescence, and proliferation kinetics in aged human primary fibroblasts.
[0023] Surprisingly and unexpectedly, components of both the ERK and AKT signaling pathways were shown to be upregulated during cellular senescence. Alterations in splicing factor expression were also observed in early passage cells exposed to cytokines. Inhibition of the AKT and ERK pathways was shown to upregulate splicing factor expression, reduce senescent cell burden, and reverse multiple cellular senescence phenotypes in a dose-dependent manner.
[0024] The dose of ERK inhibitor and / or AKT inhibitor in the above composition is preferably low.In the course of the experiment, the inventors unexpectedly found that low-dose chemical inhibition of either ERK or AKT signaling at 1 μM for 24 hours restores the expression of splicing factor to the level that is consistent with that seen in young passage cells, and causes a certain percentage of the cells tested to reverse senescence and re-enter cell cycle.
[0025] In a further aspect of the invention there is provided a composition capable of modulating expression of a splicing factor, the composition comprising one or more compounds capable of binding to, binding to or inhibiting the FOXO1 and / or ETV6 genes. Preferably the composition comprises one or more compounds capable of binding to or inhibiting the FOXO1 and ETV6 genes (or other FOXO or ETS family member genes) or their gene products.
[0026] The inventors advantageously noted that targeted knockdown of the genes encoding the downstream targets FOX01 or ETV6 was sufficient to mimic the observations found with inhibition of ERK and AKT.
[0027] The composition of the above embodiment may have several applications, from laboratory reagents and research tools to pharmaceuticals. With respect to laboratory reagents, the composition can be used as a research tool to investigate the effect of reducing gene expression of FOXO1 and / or ETV6, or to restore and / or increase expression of splicing factors, or to reduce or reverse cellular senescence and / or re-entry into the cell cycle. The composition can also be used as a method to reduce or reverse cellular senescence and / or re-entry into the cell cycle for cell culture, including stem cell culture for research and therapeutic applications. The composition could be used to increase the number of viable passages in cell culture and / or reduce the senescent cell population.
[0028] The composition may include an inhibitor of ERK or AKT signaling.
[0029] The composition may be in the form of a pharmaceutical formulation.
[0030] The composition may be for use as a medicine.
[0031] Advantageously, the results generated by the present inventors suggest that dysregulation of the expression of splicing factors and cellular senescence associated with ageing may, in part, result from altered activity of ERK and AKT signaling, acting through ETV6 and FOXO1 transcription factors. Therefore, targeting the activity of downstream effectors of ERK and AKT may be promising targets for future therapeutic intervention.
[0032] The composition may be for use in the prevention, management, amelioration, or treatment of an age-related disease or condition.
[0033] The composition may be for use in a method of prevention, management, amelioration or treatment of an age-related disease or condition, the method comprising administering a therapeutically effective amount of the composition to a subject in need thereof.
[0034] In a related aspect, the invention may include a composition for use in the manufacture of a medicament for the prevention, management, amelioration, or treatment of an age-related disease or condition.
[0035] The age-related disease or condition may include many age-related conditions, such as Alzheimer's disease, cardiovascular disease, hypertension, arthritis, osteoporosis, type 2 diabetes, cancer, Parkinson's disease, cognitive impairment or frailty. The age-related disease or condition may also include some conditions suffered by young subjects suffering from certain conditions that cause premature aging, called progeroid syndromes (premature aging syndromes), such as Werner syndrome and Hutchinson-Gilford progeria syndrome.
[0036] The composition may be for use in the prevention, management, amelioration or treatment of cancer.
[0037] The composition may be for use in a method of prevention, management, amelioration or treatment of cancer, the method comprising administering a therapeutically effective amount of the composition to a subject in need thereof.
[0038] In a related aspect, the invention may include a composition for use in the manufacture of a medicament for the prevention, management, amelioration or treatment of cancer.
[0039] The composition may also be for use as a dietary supplement or cosmetic to reduce the effects of aging.
[0040] According to a further aspect of the present invention, a) to regulate gene expression of FOXO1 and / or ETV6 or their target genes, b) to restore and / or increase expression of splicing factors, or c) To reduce or reverse cellular senescence and / or cell cycle re-entry Related combinations of ERK inhibitors and AKT inhibitors are provided.
[0041] As used herein, the terms "treatment", "treating", "treating" and the like refer to obtaining a desired pharmacological and / or physiological effect. This effect may be prophylactic in that it completely or partially prevents a disease or its symptoms, and / or it may be therapeutic in that it partially or completely cures a disease and / or the adverse effects caused by the disease. As used herein, "treatment" covers any treatment of a disease in a mammal, particularly a human, and includes (a) preventing the disease from occurring in a subject who may be predisposed to the disease but has not yet been diagnosed as having the disease, (b) inhibiting the disease, i.e., arresting or slowing the development of the disease, and (c) relieving the disease, i.e., causing regression of the disease.
[0042] As used herein, the term "subject" includes any human or non-human animal. The term "non-human animal" includes all mammals, such as non-human primates, sheep, dogs, cats, cows, horses, etc.
[0043] A "therapeutically effective amount" refers to the amount of a composition that, when administered to a subject for treating a disease, is sufficient to affect such treatment for the disease. This "therapeutically effective amount" will vary depending on the pharmaceutical active ingredient used, the disease and its severity, and the age, weight, etc., of the subject to be treated.
[0044] In general, routes of administration contemplated by the present invention include, but are not necessarily limited to, enteral, parenteral, or inhalation routes.
[0045] Parenteral administration routes other than inhalation administration include, but are not necessarily limited to, topical (local), transdermal, subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrasternal, intrathecal, and intravenous routes, i.e., any route of administration other than through the digestive tract. Parenteral administration can be carried out to effect systemic or local delivery. When systemic delivery is desired, administration typically includes invasive or systemically absorbed topical or mucosal administration of pharmaceutical formulations. Enteral administration routes include, but are not necessarily limited to, oral and rectal (e.g., using suppositories) delivery.
[0046] Conventional and pharma- ceutically acceptable routes of administration include intranasal, intramuscular, intratracheal, intrathecal, intracranial, subcutaneous, intradermal, topical (local), intravenous, intraperitoneal, intra-arterial (e.g., via the carotid artery), spinal or intracerebral delivery, rectal, nasal, oral, and other enteral and parenteral routes of administration.
[0047] In some embodiments, the composition of the invention or the combination of the invention may be administered together with one or more other compounds effective in the prevention, management, amelioration, or treatment of an age-related disease or condition or cancer.
[0048] In an alternative embodiment of the present invention, there is provided a use of a composition comprising one or more intermediate non-coding RNA regulators that regulate the expression of ETV6 for the cosmetic treatment of the effects of aging, which may include dysregulation of the expression of splicing factors and / or dysregulation of cellular senescence.
[0049] In yet a further aspect of the present invention there is provided the use of a composition comprising one or more intermediate non-coding RNA regulators that regulate expression of FOXO1 for the cosmetic treatment of the effects of ageing, wherein the effects of ageing include dysregulation of expression of splicing factors and / or dysregulation of cellular senescence.
[0050] The term "cosmetic treatment" is intended to mean any non-medical treatment that can be applied systemically or locally to humans or animals.
[0051] The term "effects of aging" is intended to mean senescence, or progressive (but not disease-based) physiological changes in humans or animals that result in a decline in biological function and a reduced ability to adapt to metabolic stress.
[0052] The FOXO1 and / or ETV6 regulator(s) or their target genes may be artificially produced. That is, they are not naturally occurring. However, the FOXO1 and / or ETV6 regulator(s) and their target genes may be naturally occurring molecules(s), but their concentration and composition in a pharmaceutical or pharmaceutical formulation or combination allows the molecule to be used for the prevention, management, improvement or treatment of age-related diseases or conditions or cancer, while otherwise the molecule will have no effect or only limited effect. The inhibitor(s) may be naturally occurring molecules(s), but it will be understood that the concentration and composition of the molecule(s) found to be therapeutically effective is not naturally occurring at such concentration or composition with other components.
[0053] The inhibitor(s) may comprise an antibody(s) or a mixture of antibodies. Such antibody(s) may be polyclonal or monoclonal. It will be clear to one skilled in the art how to produce an antibody that will act as an inhibitor. Preferably, the antibody is humanized.
[0054] In other embodiments, the inhibitor(s) comprise a peptide or a peptidomimetic thereof, or a C-terminal amidated peptide thereof.
[0055] The term "peptide" (s) includes compounds having amino acid residues (H-Cα-[side chain]) which may be linked by peptidic (-CO-NH-) or non-peptidic bonds.
[0056] The peptides may be synthesized by solid phase peptide synthesis in the Fmoc-polyamide mode.
[0057] The peptide may be a peptide aptamer, which typically consists of a short sequence of 5 to 20 amino acid residues in length that can bind to a specific target molecule.
[0058] There are several different approaches to the design and synthesis of peptide compositions that do not contain amide bonds. In one approach, one or more amide bonds are replaced with various chemical functional groups in an essentially isomeric manner.
[0059] Retro-inverso peptidomimetics, in which the peptide bonds are reversed, can be synthesized by methods known in the art. This approach involves creating pseudopeptides that contain changes involving the backbone, rather than the orientation of the side chains. Retro-inverso peptides, which contain NH-CO bonds instead of CO-NH peptide bonds, are more resistant to proteolysis.
[0060] Peptides may be linear. However, it may be advantageous to introduce cyclic moieties into peptide-based frameworks. Cyclic moieties restrict the conformational space of the peptide structure, which may lead to increased efficacy. An additional advantage of this strategy is that the introduction of cyclic moieties into peptides may also result in peptides with reduced susceptibility to cellular peptidases.
[0061] In some embodiments of the invention, the peptide may be conjugated to another site. Convenient sites to which the peptide may be conjugated include polyethylene glycol (PEG) and peptide sequences such as TAT and antennapedia that enhance delivery to cells.
[0062] In some embodiments, the inhibitor(s) are prodrugs of the peptide. A prodrug is a compound that is metabolized in vivo to produce a molecule such as a protein. Those skilled in the art will be familiar with the preparation of prodrugs.
[0063] The peptide may be a peptidomimetic. A peptidomimetic is an organic compound that has a similar structure (geometry) and polarity to the molecules defined herein and has a substantially similar function. A mimetic is one in which the NH group of one or more peptide linkages is replaced by a CH 2 The mimetic may be a molecule in which one or more amino acid residues are replaced with an aryl group, such as a naphthyl group.
[0064] In other embodiments, the inhibitor(s) comprise nucleic acids such as single-stranded DNA or RNA that can bind to and inhibit downstream effectors of FOXO1 and / or ETV6 or their target genes. It is envisaged that the same targets are also suitable for targeting with peptides, and that peptide aptamers are also suitable for targeting with RNA or modified RNA aptamers. Nucleic acids such as single-stranded DNA and RNA that bind to and inhibit downstream effectors of FOXO1 and / or ETV6 or their target genes may be provided. Typically, the nucleic acid is single-stranded and has 100-50000 bases.
[0065] In yet other embodiments, the inhibitor(s) is a small molecule or comprises a small molecule.
[0066] It will be apparent to one of skill in the art if the composition is intended to include one or more compounds capable of binding to or modulating expression of the FOXO1 and / or ETV6 gene or its gene products.
[0067] It should be understood that features, integers, properties, compounds, molecules, chemical moieties or groups described in connection with a particular aspect, embodiment or example of the invention are also applicable to other aspects, embodiments or examples described herein, unless to the contrary. All of the features disclosed herein (including any accompanying claims, abstracts and figures) and / or all of the steps of any method or process so disclosed may be combined in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. The invention is not limited to the details of any of the embodiments described above. The invention also extends to any novel one or any novel combination of features disclosed herein (including any accompanying claims, abstracts and figures) or any novel one or any novel combination of steps of any method or process so disclosed. [Brief description of the drawings]
[0068] [Figure 1] Figure 1 shows the difference in the proliferative cell fraction between early and late passage (senescent) cell cultures. Early and late passage cell cultures were subjected to 24 hours of labeling with the S-phase marker BrdU to selectively stain actively growing cells. ***=p=<0.0001, n=3 biological replicates, 300 nuclei counted per replicate. [Diagram 2]Figure 2 shows age-related changes in protein phosphorylation for targets within the ERK and AKT pathways. A, Graph showing that phosphorylated protein expression of key targets from the AKT and ERK pathways was assessed in young (PD=25) and senescent (PD=63) cells. White and grey bars represent young and senescent cell lysates, respectively. B, Schematic diagram showing genes tested for senescence-associated phosphorylation differences in the AKT and ERK pathways. Targets showing significantly different phosphorylation levels are highlighted in bold underline. Targets showing no significant differences in protein phosphorylation are displayed in regular typeface. Statistical significance is indicated by an asterisk with *p<0.05. Error bars indicate standard error of the mean. [Diagram 3]Figure 3 shows that chemical inhibition of ERK or AKT signaling is associated with rescue from the cellular senescence phenotype. A. The percentage of cells staining positive for senescence-associated β-galactosidase (SA-β-Gal) activity after treatment with 1 μM or 10 μM trametinib and SH-6 was determined by manually counting the percentage of SA-β-gal positive cells. N=>300 cells for each sample. B. The levels of the senescence-associated transcript CDKN2A, which encodes the senescence marker p16, were assessed in senescent cells by qRTPCR. Data are given in relative expression to stable endogenous control genes GUSB, IDH3B and PPIA, normalized to the levels of individual transcripts present in control cells treated with vehicle only. Fold changes were calculated in triplicate for three biological replicates. Statistical significance is indicated at **p<0.005, ***p<0.0001 (two-way ANOVA). C. Protein levels of various pro-inflammatory SASP factors after treatment with 1 μM and 10 μM ERK and AKT inhibitors. D. Expression levels of CDKN1A transcripts encoding the DNA damage response protein p21. E. Heatmap showing fold change in SASP protein expression. Green indicates upregulation and red indicates downregulation. Only statistically significant changes are displayed in the heatmap. Color scale refers to percent change in expression. Experiments were performed in duplicate for a total of six biological replicates. Error bars indicate standard error of the mean. [Figure 4] Figure 4 shows the effect of ERK or AKT inhibitors on splicing factor expression and senescent cell burden under conditions not allowing cell proliferation. To establish whether the apparent "rejuvenation" of senescent cell cultures stems from changes in the proliferation kinetics of non-senescent cells in culture or results from a true rescue in response to treatment, selected experiments were repeated under conditions of serum starvation, where cells were prevented from dividing. A. Ki67 staining showed that cells were non-proliferative, whereas B. SA-b-Gal staining revealed that rescue was still evident. ***=p=<0.0001, n=3 biological replicates, 300 nuclei counted per replicate. [Diagram 5]Figure 5 shows changes in phosphorylation status of ERK and AKT signaling proteins, and proteins of linked signaling pathways, in response to low-dose inhibition of ERK or AKT. White, light grey, light grey hatched, dark grey and dark grey hatched boxes represent control, low-dose trametinib, high-dose trametinib, low-dose SH-6 and high-dose SH-6, respectively. Statistical significance is indicated by stars, *p<0.05. Error bars indicate standard error of the mean. ***=p=<0.0001. Data are from three biological replicates and two technical replicates. [Figure 6] Figure 6 shows that inhibition of the AKT or ERK pathway affects the expression of splicing factor transcripts and cell proliferation rates. A. Changes in splicing factor mRNA levels in response to 24 h treatment with 1 μM and 10 μM ERK or AKT inhibitors. Green indicates upregulated genes, red represents downregulated genes. Color scale indicates fold change in expression. Only statistically significant changes are displayed in the heatmap. B. Proliferation index was assessed by Ki67 immunofluorescence (>400 nuclei were counted per sample) and evaluated for treated cells. C. Cell numbers after treatment with 1 μM and 10 μM ERK or AKT inhibitors. D. Telomere length quantified by qPCR relative to the 36B4 endogenous control and normalized to the telomere length in the vehicle only control. E. Apoptotic index of senescent cells treated with inhibitors as determined by TUNEL assay. Data are from duplicate studies of three biological replicates. Statistical significance is indicated as **p<0.005, ***p<0.0001. Error bars indicate standard error of the mean. [Figure 7]FIG. 7 shows the cellular and molecular effects of targeted knockdown of ETV6 and FOXO1 genes. A. Levels of expression of splicing factors after FOX01, ETV6 or ETV6 / FOX01 gene knockdown. Green indicates upregulated genes and red represents downregulated genes. Color scale indicates fold change in expression. Only statistically significant changes are displayed in the heatmap. B. Senescent cell burden indicated by SA-β-Gal after FOX01, ETV6 and ETV6 / FOX01 gene knockdown. n>300 cells for each sample. C. Senescent cell burden indicated by CDKN2A gene expression after FOX01, ETV6 and ETV6 / FOX01 gene knockdown. Data are expressed relative to stable endogenous control genes GUSB, IDH3B and PPIA and normalized to the levels of individual transcripts in vehicle only controls. D. Proliferation index was assessed by Ki67 immunofluorescence (more than 400 nuclei were counted per sample) after FOX01, ETV6 and ETV6 / FOX01 gene knockdown. E. Effect of FOX01 or ETV6 gene knockdown on the reciprocal expression of ETV6 and FOXO1 genes, respectively. Data are expressed relative to stable endogenous control genes GUSB, IDH3B and PPIA and normalized to the levels of individual transcripts in the control. Data are from duplicate studies of three biological replicates. Statistical significance is indicated by *p<0.05, **p<0.005, ***p<0.0001. Error bars indicate standard error of the mean. [Figure 8]Figure 8 shows the effect of FOXO1 and / or ETV6 knockdown achieved by siRNA, the second methodology. The effect of ETV6 or FOXO1 gene knockdown was confirmed by siRNA against the gene of interest. The level of knockdown was determined to be 43% for ETV6 and 65% for FOXO1. Effect of gene knockdown on splicing factor expression (A), effect on ETV6 and FOXO1 expression (B). The identity of the manipulated genes is given on the x-axis. The first four bars show the effect on FOXO1 gene expression, the latter on ETV6 expression. The effect on senescent cell burden (C) and CDKN2A expression (D) was also examined. Only statistically significant changes are displayed in the heatmap. ***=p=<0.0001, n=3 biological replicates. Data are from three independent biological replicates. [Figure 9] FIG. 9 shows the effect of ERK or AKT inhibition on the expression and subcellular localization of FOXO1 and ETV6 transcripts. A. Effect of ERK and AKT inhibition on ETV6 and FOXO1 expression. Treatments are indicated on the x-axis. The first five bars show the effect on FOXO1 expression, and the second five bars show the effect on ETV6 expression. Data are from three independent biological replicates, each with three technical replicates. B. Effect of ERK and AKT inhibition on the subcellular localization of ETV6 and FOXO1 proteins. Treatments are indicated on the x-axis. The first five bars show the effect on ETV6 localization, and the second five bars show the effect on FOXO1 localization. ***=p=<0.0001. Data are from at least 50 cells from each of three independent biological replicates. [Figure 10] FIG. 10 is a schematic diagram showing the indirect control of aging elucidated by the experiments carried out by the present inventors. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0069] Embodiments of the invention will now be described, by way of example only, with reference to the accompanying drawings. EXAMPLES
[0070] The aim of the present experiments was to investigate the effects of manipulation of the ERK and AKT signaling pathways by chemical inhibition or targeted gene knockdown on splicing factor expression and cellular senescence and proliferation kinetics in late passage human primary fibroblasts.
[0071] 1. Increased phosphorylation of MEK / ERK and PI3K / AKT pathway target proteins in senescent cells Cell cultures were considered senescent when population doubling times slowed to less than 0.5 cell divisions per week. At this time point, only 3% of cells stained positive for the S-phase marker BrdU, which indicates active DNA replication (Figure 1). Late passage primary human dermal fibroblasts were found to have reached senescence at PD=63. Earlier passage cells were at PD=25. We noted increased phosphorylation of AKT, CREB, ERK, GSK3α, MEK, and MSK2 signaling proteins in late passage fibroblasts, but not GSK3β, HPS27, JNK, MKK3, MKK6, mTOR, p38, p58, p70SK6, or RSK1 proteins in these cells (Figure 2A). Several of these targets are in the AKT or ERK signaling pathways (Figure 2B).
[0072] 2. Inhibition of MEK / ERK and PI3K / AKT pathways rescues the senescent phenotype We evaluated the effect of targeted inhibition of AKT or MEK / ERK in late passage human primary fibroblasts using specific inhibitors. Upon treatment with both 1 μM and 10 μM SH-6 (AKT) or trametinib (MEK / ERK), SH-6 and trametinib at both high and low doses, respectively, resulted in a specific decrease in phosphorylation of AKT or ERK proteins (Figure 3A). This was accompanied by a slight but definite reduction in the senescent cell population, as shown by a decrease in SA-β-Gal staining (p=<0.0001; Figure 3B) and a decrease in the expression of both p16 and p21 (Figures 3C and 3D). Decreased levels of several secreted SASP proteins were also observed in cells treated with both low and high doses of trametinib and SH-6 (Table 1 below; Figure 3E).
[0073] [Table 2] (Protein levels of pro-inflammatory components of the senescence-associated secretory phenomenon (SASP) were measured using the Mesoscale ELISA platform in media from senescent cells treated for 24 h with 1 μM or 10 μM of the ERK inhibitor trametinib or the AKT inhibitor SH-6. Results are expressed as percentage of control values (vehicle only) of three independent experiments. Standard error of the mean (SEM) is given in brackets. Statistical significance compared to the corresponding control values. * p<0.05, ** p<0.005 and *** p<0.001 is indicated by an asterisk.)
[0074] To establish whether the decline in the senescent cell fraction was due to active "rescue" or simply increased proliferation of growth-arrested cells in culture, we repeated the treatment under conditions of serum starvation, which inhibits cell proliferation. Cells under serum starvation showed a reduction of approximately 20% in SA-β-Gal positive cells, indicating that the effect was not simply due to a change in the division rate of cultured cells (Figure 4). This is consistent with our previous findings (Latorre et al., 2017).
[0075] 3. Inhibition of MEK / ERK and P13K / AKT alters the phosphorylation state of both upstream and downstream target proteins of ERK and AKT To investigate potential downstream targets that may affect cellular senescence, we assessed the effect of inhibition of ERK and AKT on downstream signaling targets. As expected, changes in phosphorylation levels of ERK and AKT were observed in response to high and low doses of pathway inhibition, along with changes in the phosphorylation status of downstream targets GSK3α, GSK3β, p70SK6, and CREB. Downregulation of GSK3β was evident for both high and low concentrations of trametinib, but only for high dose SH-6, whereas phosphorylation of GSK3α showed decreased levels at low doses and increased levels at high doses in both trametinib alone and SH-6 alone, but was statistically significant only for high dose SH-6 and low dose trametinib (Figure 5A). This pattern of antagonism was also evident for upstream kinases, including p38. Several other upstream targets, including p53, MKK3, MKK6, and MEK, showed differences in phosphorylation state following treatment, with effects most prevalent at the higher doses (Figure 5B).The changes in p53 phosphorylation are consistent with the restoration of cells to a more proliferative, less senescent state by treatment with AKT or ERK inhibitors (Pise-Masison et al., 1998).
[0076] 4. ERK and AKT pathways affect splicing factor expression Dysregulation of splicing factor expression has been linked to cellular senescence and ageing in human populations and cells (Harries et al., 2011; Holly et al., 2013) and in animal models (Heintz et al., 2016; Lee et al., 2016). Moreover, restoration of splicing factor expression using small molecules was associated with rescue of cellular senescence in our previous studies (Latorre et al., 2017). Therefore, we assessed the expression of an a priori list of 20 splicing regulator genes previously demonstrated to show senescence-associated changes in late passage human fibroblasts treated with low (1 μM) and high (10 μM) doses of AKT and ERK inhibitors (SH-6 and trametinib, respectively). Treatment with both trametinib and SH-6 at low doses (1 μM) was associated with upregulation of multiple splicing factors (Figure 6A; Table 2 below).
[0077] [Table 3] (Changes in mRNA levels in senescent primary human fibroblasts in response to 24 h treatment with 1 μM or 10 μM of an ERK inhibitor (trametinib) or an AKT inhibitor (SH-6). Data are from duplicate studies of three biological replicates. Standard error of the mean (SEM) is given in brackets. Statistical significance compared to corresponding control values. * p<0.05, ** p<0.005 and *** p<0.0001 indicated by an asterisk.)
[0078] The effect was more pronounced in cells with MEK / ERK inhibition than in cells with AKT inhibition. Surprisingly, high doses of inhibitors (10 μM) revealed antagonistic effects on splicing factor expression (Fig. 6A; Table 2). This dose-dependent response was also observed for proliferation kinetics (Fig. 6B, C). Low doses of trametinib led to a 31% increase in the proliferation index, whereas low doses of SH-6 led to a 27% increase in Ki67 staining (p=<0.0001 and <0.0001, respectively). High dose treatment with either inhibitor did not lead to reactivation of proliferation (Fig. 6B, C). These data show a clear link between re-entry into the cell cycle and expression of splicing factors. No telomere rescue was evident with any treatment (Fig. 7D), and no increase in the apoptotic index was observed with any treatment (Fig. 7E).
[0079] 5. ETV6 and FOXO1 are regulators of splicing factor expression and cellular senescence phenotype ERK and AKT signaling have multiple downstream effector pathways with significant evidence of crosstalk and autoregulation (Rhim et al., 2016). To clarify the mechanism, it was necessary to identify the downstream effector genes to give a clearer assessment of the phenotype upon manipulation. Targeted deletion of Foxo and Aop genes has been reported to be associated with lifespan extension in D. Melanogaster (Slack et al., 2015), the closest human homologs of which are FOXO1 and ETV6 (Jousset et al., 1997; Kramer et al., 2003). Targeted gene knockdown using morpholino oligonucleotides revealed that downregulation of either FOXO1 or ETV6 in late passage human primary fibroblasts resulted in rescue of splicing factor gene expression similar to that seen with AKT or ERK inhibition, although the results were more pronounced for FOXO1 (Figure 7A). The changes in splicing factor expression were accompanied by a reduction in senescent cell burden of approximately 18% and 40% for ETV6 and FOXO1 knockdown, respectively, as measured by SA-β-Gal staining (p=<0.0001 and 0.0001; Fig. 7B), with a corresponding reduction in CDKN2A expression of 24% and 43% (p=<0.05 and <0.005 for ETV6 and FOXO1, respectively; Fig. 7C). This represents a more pronounced change than inhibiting either ERK or AKT signaling overall. Again, as we noted for splicing factor expression, the effect was strongest in cells where FOXO1 expression was manipulated. Cell proliferation was also restored in late passage fibroblasts in which ETV6 or FOXO1 expression was inhibited. Knockdown of ETV6 resulted in a 36% increase in the proliferation index, whereas inhibition of FOXO1 resulted in a 19% increase (p=<0.0001 and <0.005, respectively; Figure 4D). The effect of knockdown of ETV6 or FOXO1 genes was also confirmed on the levels of splicing factor expression, cellular senescence, and CDKN2A expression using siRNAs targeted to the genes of interest (Figure 8).
[0080] 6. There is significant cross-regulation between the AKT and ERK signaling pathways Cross-regulatory relationships emerged between both the ERK and AKT signaling pathways, as well as between ETV6 and FOXO1 itself. Double knockdown of both ETV6 and FOXO1 genes inhibited rescue from multiple senescent phenotypes (Figure 7B-D). Some of the coregulation may be partly at the level of transcriptional interactions. Knockdown of the ETV6 gene affected the expression of both ETV6 and FOXO1 genes, whereas knockdown of the FOXO1 gene was associated with downregulation of FOXO1 levels only (Figure 8B). Similar cross-regulation is seen in the response of FOXO1 and ETV6 gene expression to ERK or AKT inhibitors. Treatment of senescent cells with low doses of trametinib induced the expression of both ETV6 and FOXO1 at the mRNA level, whereas treatment with low doses of SH-6 caused upregulation of only FOXO1 (Figure 9A). This may represent a compensatory counterregulation at the mRNA expression level, although this remains to be confirmed. High doses of SH-6 caused a significant downregulation of both FOXO1 and ETV6 expression, whereas high doses of trametinib were associated with changes in FOXO1 expression only (Figure 9A). Treatment with trametinib or SH-6 also caused some small but significant changes in the subcellular localization of ETV6 and FOXO1 proteins. Low doses of trametinib were associated with more nuclear retention of ETV6 protein, but less nuclear retention of FOXO1 protein. High doses of trametinib were associated with less nuclear FOXO1 protein only. Low doses of SH-6 were associated with a significant decrease in the nuclear retention of ETV6, but FOXO1 subcellular localization was unaffected. High doses of SH-6 caused a decrease in the nuclear localization of both ETV6 and FOXO1 proteins (Figure 9B). These data indicate that interactions between FOXO1 and ETV6 occur at both the transcriptional and protein localization levels, as well as cross-regulation at the level of protein activity, as shown here and in previously published data (Rhim et al., 2016). Cross-regulation is typical of these signaling pathways and is worth exploring in the future.
[0081] 7. Splicing factors are indirect targets of FOXO1 and ETV6 The target genes of FOXO1 and ETV6 were compared by analysis of publicly available chromatin immunoprecipitation (ChIP) datasets from human cell types. 419 target genes of ETV6 and 242 target genes of FOX01 were identified. All 242 targets of FOX01 were also targets of ETV6. Two splicing factors (HNRNPF and HNRNPLL) were direct targets of ETV6, but most splicing factors were not directly targeted, suggesting that regulation by these proteins is indirect. Target genes of FOXO1 and ETV6 included several molecular functions, but surprisingly, almost a quarter (58 / 242) of genes targeted by both ETV6 and FOXO1 included noncoding RNA regulators (miRNAs, snoRNAs, lncRNAs), transcription factors, or cell signaling proteins (Table 3 below).
[0082] [Table 4(1)]
[0083] [Table 4(2)]
[0084] [Table 4(3)]
[0085] [Table 4(4)]
[0086] [Table 4(5)]
[0087] [Table 4(6)]
[0088] Also of interest was the observation that in four cases, both the coding RNA coupling modules and their cognate noncoding RNA regulators were targeted by FOXO1 and ETV6 (AP4B1 and AP4B1-AS1; CD27 and CD27-AS1; PCOLCE and PCOLCE-AS1; RAMP2 and RAMP2-AS1). Gene set enrichment analysis (GSEA) suggested that FOXO1 and ETV6 target genes were clustered in pathways involved in the aging process. The top four pathways highly associated with targets of both genes were "Sensation-associated secretory phenomenon (SASP)" (p=0.0002 for ETV6 and 0.0003 for FOXO1), "Mitotic prophase" (p=0.0004 for ETV6 and 0.0003 for FOXO1), "Cellular senescence" (p=0.0021 for ETV6 and 0.0001 for FOXO1), and "M-phase" (p=0.0045 for ETV6 and 0.0001 for FOXO1) (see Table 4 below).
[0089] [Table 5]
[0090] Consideration Receptor tyrosine kinases integrate multiple signals from inside and outside the cell and transmit this information to cellular control mechanisms. Our data suggest that proteins involved in the ERK and AKT signaling pathways show higher levels of phosphorylation in late passage cells, indicating significant cross-regulation and autoregulation. We propose that a major downstream consequence of this may be dysregulation of splicing factor expression in late passage cells, mediated primarily by changes in the activity and cross-reactivity of FOXO1 and ETV6 transcription factors, and that these changes are associated with the senescent phenotype in this line. Low-dose chemical inhibition of either ERK or AKT signaling, or reduction of FOXO1 or ETV6 gene expression in late passage human primary fibroblasts, restored splicing factor expression to levels consistent with those seen in younger passage cells, and led to reversal of senescence and re-entry into the cell cycle in a proportion of cells tested.
[0091] The ERK and AKT signaling pathways can be activated by classical aging stimuli such as DNA damage, dysregulated nutrient signaling, and chronic inflammation associated with aging (Fontana et al., 2012; Lin et al., 2013). The NF-kβ pathway, a major contributor to senescence-associated secretory phenomena (SASP), is also known to be activated by both ERK and AKT signaling (Lin et al., 2012), raising the possibility of a vicious cycle of positive feedback. Dysregulation of normal splicing processes is a key feature of many age-related diseases such as Alzheimer's disease, Parkinson's disease, and cancer (Latorre and Harries, 2017). Altered splicing regulation has been associated as such with aging in human populations (Harries et al., 2011), cellular senescence in in vitro models (Holly et al., 2013), and longer lifespan in mouse models (Lee et al., 2016). Some studies suggest that splicing control may be on the causal pathway of aging, as targeted disruption of specific splicing factors can regulate lifespan in invertebrate models (Heintz et al., 2016). Our recent work suggests that hallmarks of cellular aging can be reversed by small molecule restoration of splicing factor levels (Latorre et al., 2017). Recent thinking suggests that changes in the decision-making process surrounding exactly which isoforms are expressed from a gene may directly contribute to senescence and age-related phenotypes (Deschenes and Chabot, 2017).
[0092] Altered cell signaling is a key feature of aging. The actions of pathways such as mTOR and IGF-1 signaling are well known and well defined (Cohen and Dillin, 2008). Both ERK and AKT signaling have been previously implicated in senescence and aging phenotypes (Demidenko et al., 2009; Chappell et al., 2011), and alterations in these pathways have also been linked to lifespan extension and aging phenotypes in animal models (Slack et al., 2015). Both ERK and AKT have previously been associated with the regulation of splicing factor activity (Shin and Manley, 2004; Tarn, 2007), and AKT is known to have a role in regulating splicing factor genes at the level of kinase activation (Blaustein et al., 2005). However, the study of the exact underlying mechanisms by which these pathways may control splicing factor expression and affect the senescent phenotype is fraught with challenges, as, as we have demonstrated, these pathways show distinct tissue, dose and context effects, as well as significant crosstalk between them (Rhim et al., 2016). This suggests that results may not be consistent at different doses of inhibitors, and effects seen in one cell type may not necessarily apply in another. This is evident from our data, which pointed to a distinct effect of dose. At low doses, we observed increased expression of some splicing factors, rescue of the senescent phenotype, and re-entry into the cell cycle, whereas at high doses, splicing factor expression was reduced and no increase in the proliferation index was observed. This suggests that other feedback loops within the AKT and ERK signaling pathways may be activated that, when activated at high doses, lead to inhibition of splicing factor expression and proliferation. Again, this may result from a feedback loop within the AKT or ERK signaling pathways that leads to inhibition of expression and proliferation of splicing factors that may be activated at higher concentrations.This is because antagonistic effects in terms of dosage or tissue response are not uncommon in intracellular signaling pathways (Pardo et al., 2003; Wang et al., 2017). Indeed, our data indicate the presence of several cross-regulatory and autoregulatory feedback loops, which may indicate that the expression of splicing factors is tightly controlled by homeostatic mechanisms within fairly narrow expression limits, which would be consistent with their known role in controlling proliferation and the combinatorial dose-responsive nature by which they control alternative splicing (Kang et al., 2009; Anczukow et al., 2012; Fu and Ares, 2014).
[0093] More detailed molecular analyses are needed to better understand the precise relationship between altered ERK and AKT signaling, splicing factor expression, and cellular senescence. Our data suggest that many of the hallmarks of AKT and ERK activation on splicing factor expression and cellular senescence phenotypes may be recapitulated by targeted disruption of FOXO1 and ETV6, two major downstream effectors of ERK or AKT signaling. The FOXO1 and ETV6 genes both encode transcription factors, of which the closest Drosophila homologs (Foxo and Aop) have been reported to contribute to the effects of ERK and AKT activation on lifespan in Drosophila melanogaster (Slack et al., 2015). FOXO proteins have a long history of involvement in aging pathways. FOXO proteins are well known to be involved in longevity in nematodes, flies, and mammals (Salih and Brunet, 2008), but to our knowledge, they have never been linked to the regulation of splicing factors before.
[0094] Targeted knockout of either gene resulted in both increased expression of splicing factors and rescue from senescence. Again, the relationship between these genes may not be synergistic, as simultaneous knockout of both genes did not produce additive or multiplicative effects on splicing factor expression and senescent cell burden, but rather the effect was completely abolished. This may be partially explained by the reciprocal regulation of FOXO1 and ETV6 genes at the level of transcription and protein subcellular localization; that is, knockdown of FOXO1 increases ETV6 expression, and modulation of either signaling pathway by specific inhibitors affects the nuclear localization of both genes. Several splicing factors have evolutionarily conserved FOXO-binding motifs in their promoter regions (Webb et al., 2016), and FOXO1 protein has been reported to colocalize with nuclear puncta in cells where splicing occurs (Arai et al., 2015). ETV6 is a member of the ETS family of transcription factors with well-known roles in controlling cell proliferation and hematopoietic cancers (Hock and Shimamura, 2017), but is perhaps a less obvious candidate as a longevity gene. Like FOXO1, ETV6 has not been previously reported as a regulator of splicing factor expression, although other members of the broader ETS family of genes with very similar binding sites have been reported to have such activity (Kajita et al., 2013). Both FOXO1 and ETV6 have been reported to have activity as tumor suppressor genes (Dansen and Burgering, 2008; Rasighaemi and Ward, 2017), so a role in negatively regulating the expression of genes required for cell proliferation is not unexpected.
[0095] ChIP analysis indicates that although FOXO1 and ETV6 may directly regulate some splicing factors (HNRNPF, HNRNPL), most regulators of splicing factor expression rather act through a series of intermediates, of which almost 25% are non-coding RNAs. Nine of the common targets are components of the U1 or U5 spliceosome complexes, thus directly implicating the splicing process. There is a striking overlap between genes regulated by FOXO1 and ETV6, suggesting that regulation may be cooperative or competitive. We speculate that this regulation may also involve the action of other FOXOs and other ETS family members. A role for these genes in mediating the aging process is also suggested by our GSEA results. Targets of FOXO1 and ETV6 are clustered into fundamental pathways of aging ("senescence-associated secretory phenomenon (SASP)", "cellular senescence", "M-phase", and "mitotic cell division cycle"). Thus, our data provide evidence that FOXO1 and ETV6 may coordinately regulate a module of mediator genes involved in the regulation of splicing factors and influence their relationship to senescence.
[0096] Our data suggest that ETV6 and FOXO1 may have activity as novel regulators of splicing factor expression, but do not exclude the contribution of other genes in these networks. Indeed, although the overall picture is similar, some splicing factor genes behave differently when challenged with pathway-wide inhibition compared to the specific inactivation of FOXO1 or ETV6 (e.g., SRSF3, SRSF6 for ERK signaling, and AKAP17A, LSM2 and LSM14A for AKT signaling). This strongly suggests the presence of other regulators. It is also clear that only a subset of cells is rescued, as the entire cell population is not reverted. Even "clonal" cultures of senescent cells are heterogeneous, containing growth-arrested but non-senescent and senescent cells, depending on the degree of paracrine inhibition. The percentage of senescent cells at growth arrest can range from about 40% to more than 80%, even in different cell lines of the same tissue type.
[0097] In conclusion, we present here evidence that activation of ERK and / or AKT signaling by age-related phenomena can lead to a cascade of events culminating in altered activity of FOXO1 and ETV6 transcription factors. Here, we show for the first time that ETV6 and FOXO1 are novel regulators of splicing factor expression and that age-related changes in their activity lead to splicing dysregulation and ultimately cellular senescence. Inhibitors of the AKT and ERK signaling pathways are already used as therapeutic agents for cancer, raising the intriguing possibility that genes in these pathways may in future represent targets for early intervention for healthy aging.
[0098] Experimental procedure Culture of human primary fibroblasts Normal human dermal fibroblasts (NHDF; Promocell, Heidelberg, Germany) derived from neonatal foreskin from a single donor were cultured at 6 × 10 3 cells / cm 2 Cells were cultured at a seeding density of 10 μM. Early passage cells at population doubling (PD) = 25 (85% growth and 7% senescence fraction) or late passage cells at PD = 63 (33% growth and 58% senescence fraction) were maintained in culture for 10 days prior to subsequent experiments. Inhibitors of MEK / ERK (trametinib) and AKT (SH-6) were added at 1 μM or 10 μM for 24 h based on previous studies in the literature (Krech et al., 2010; Slack et al., 2015). Vehicle only (DMSO) controls were included in each experiment. When serum starvation was required to differentiate senescence rescue from altered proliferation kinetics, cells were maintained in DMEM supplemented with 0.1% serum and 1% penicillin and streptomycin in the absence of fibroblast-specific supplements (Sigma Aldrich, Dorset, UK) for 24 h prior to treatment.
[0099] Assessment of phosphorylation changes in key signaling pathways during cellular senescence 25 cm of early and late passage primary human fibroblasts 2 6 x 10 in flask 3 cells / cm 2Cells were plated at a density of 1000 x 1000 and grown for 10 days. The phosphorylation status of proteins in key signaling pathways thought to be activated in senescence was then assessed in cell lysates from early passage (PD=25) or late passage (PD=63) primary human fibroblasts using a human MAPK phosphorylation antibody array (ab211061, Abcam, Bristol, UK) according to the manufacturer's instructions. The phosphorylation sites tested were: AKT(pS473), CREB(pS133), ERK1(pT202 / Y204), ERK2(pT185 / Y187), GSK3a(pS21), GSKb(pS9), HSP27(pS82), JNK(pT183), MEK(pS217 / 221), MKK3(pS189), MKK6(pS207), MSK2(pS360), mTOR(pS2448), p38(pT180 / Y182), p53(pS15), P70S6K(pT421 / S424), RSK1(pS380). Briefly, membranes were blocked with blocking buffer for 30 min at room temperature and 1 ml of cell lysate was incubated overnight at 4°C. After washing, detection antibody cocktail was added and incubated for 2 h, followed by incubation with HRP anti-rabbit IgG at room temperature for 2 h. Membranes were incubated with detection buffer and results were recorded on a chemiluminescence imaging system (LI-COR biosciences, NE, USA). Signal intensity was quantified using Image Studio software V5.2 (LI-COR biosciences, NE, USA). Results were normalized to total cellular protein content and expressed relative to the positive control.
[0100] Assessment of cellular senescence Late passage primary human fibroblasts (PD=63) were cultured in a 6-well plate at 6 × 10 4Cells were seeded in three biological replicates. Cells were treated for 24 h with the MEK / ERK inhibitor trametinib or the AKT inhibitor SH-6 at 1 μM and 10 μM, or with a combination of the two inhibitors at 1 μM each. Cell senescence was then assessed using the biochemical senescence marker SA β-Gal, tested in triplicate using a commercially available kit (Sigma Aldrich, UK). A minimum of 400 cells were assessed per replicate, following the manufacturer's instructions. Senescence was also quantified molecularly by assessing the expression of the CDKN2A(p16) gene, and by changes in cell morphology typical of senescence, similar to our previous study (Holly et al., 2013). CDKN2A (p16) was measured by qRTPCR relative to GUSB, PPIA and GADPH endogenous control genes on a QuantStudio 12K Flex platform (Applied Biosystems, Foster City, USA). PCR reactions contained 2.5 μl TaqMan Universal Mastermix (no AMPerase) (Applied Biosystems, Foster City, USA), 0.25 μM probe and 0.5 μl cDNA reverse transcribed as above in a total volume of 5 μl. PCR conditions were one cycle of 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Accession numbers of the quantitative RTPCR assays for p16 and p21 are given in Table 5 below.
[0101] [Table 6]
[0102] Quantification of treatment-associated changes on SASP protein expression Late passage primary human fibroblasts (PD=63) were plated in a 6-well plate at 6 × 10 cells per well. 4Cells were seeded and cultured for 10 days and then treated with 1 μM or 10 μM trametinib (MEK / ERK inhibitor) or SH-6 (AKT inhibitor) for 24 h. Cell supernatants were then harvested and stored at -80°C. Levels of GMCSF, IFNγ, IL1β, IL2, IL6, IL8, IL10, IL-12p70 and TNFα SASP components were measured in cell supernatants of treated and vehicle-only control cells in four biological replicates using K15007B MesoScale Discovery multiplex ELISA immunoassays (MSD, Rockville, USA). Proteins were quantified relative to a standard curve using a Sector Imager SI-6000 according to the manufacturer's instructions.
[0103] Assessment of splicing factor expression in late passage primary human fibroblasts treated with ERK or AKT inhibition Plate late passage primary human fibroblasts at PD=63 in 6-well plates as three biological replicates, 6 x 10 per well. 4Cells were seeded and grown for 10 days before being treated with 1 μM or 10 μM of the ERK inhibitor trametinib or the AKT inhibitor SH-6 for 24 h. Vehicle (DMSO) only controls were also included with the same growth conditions. Next, expression levels of 20 splicing factor transcripts previously associated with age, replicative senescence or life span in our previous studies (Harries et al., 2011; Holly et al., 2013; Lee et al., 2016) were assessed by qRTPCR. Accession numbers for splicing factor assays are given in Table 5. RNA was extracted using TRI Reagent® (Life Technologies, Foster City, USA) according to the manufacturer's instructions. Total RNA (100 ng) was reverse transcribed in a 20 μl reaction using the Superscript III VILO kit (Life Technologies). Transcript expression was then quantified in duplicate for each biological replicate using TaqMan Low Density Array (TLDA) on a QuantStudio 12K Flex (Applied Biosystems, Foster City, USA). Cycling conditions were 1 cycle each of 50°C for 2 min, 94.5°C for 10 min, followed by 40 cycles of 97°C for 30 s and 57.9°C for 1 min. The reaction mixture consisted of 50 μl TaqMan Fast Universal PCR Mastermix (Life Technologies), 30 μl dHO, 10 μl PBS, 10 ... 2 The reaction mixture contained 20 μl of 0 and 20 μl of cDNA template. 100 μl of the reaction mixture was dispensed into the TLDA card chamber and centrifuged twice for 1 min at 1000 rpm. Transcript expression was assessed by a comparative Ct approach relative to the IDH3B, GUSB and PPIA endogenous control genes and normalized to their expression in RNA from untreated late passage cells.
[0104] Assessment of cell proliferation The proliferative potential of treated cells was assessed by Ki67 and BrdU staining, as well as by cell count. Late passage primary human fibroblasts at PD=63 were plated in 24-well plates at 1 × 10 per well in three biological replicates.4 Cells were seeded and grown for 10 days and then assayed for cell proliferation by ki67 staining. For assessment of cells in S phase, late passage primary human fibroblasts at PD=63 were plated in 24-well plates in three biological replicates at 1 × 10 per coverslip. 4 Cells were seeded and grown for 10 days and then incubated with 5-bromo-2'-deoxy-uridine (BrdU) for 24 h. BrdU incorporation was determined by 5-Bromo-2'-deoxy-uridine labeling and detection kit I according to the manufacturer's instructions (Roche Molecular Biochemicals). BrdU-positive cells were visualized by fluorescence microscopy and counted. Cell counts were performed manually in three biological replicates, in treated and vehicle-only cultures, after trypsinization and suspension of cells, and are presented as mean values (+ / SEM). After treatment, cells were fixed with 4% PFA for 10 min and permeabilized with PBS containing 0.025% Triton and 10% serum for 1 h. Ki-67 staining was performed with rabbit monoclonal antibody (ab16667, Abcam, UK) diluted 1:400, samples were incubated overnight at 4 °C, then incubated with FITC-conjugated secondary goat anti-rabbit antibody (1:400) for 1 h, and nuclei were counterstained with DAPI. Coverslips were mounted on slides in DAKO fluorescent mounting medium (S3023; Dako, Santa Clara, USA). Proliferation index was determined by counting the percentage of Ki67-positive cells from at least 400 nuclei from each biological replicate under a Leica D4000 fluorescent microscope at 400× magnification.
[0105] Assessment of apoptosis using the TUNEL assay Terminal DNA breakpoints in situ 3-hydroxy end labeling (TUNEL) assay was performed to quantify the level of apoptosis in NHDF cells. Late passage primary human fibroblasts at PD=63 were plated in 24-well plates with three biological replicates at 1 × 10 per well. 4 Cells were seeded and grown for 10 days and TUNEL assays were performed using the Click-iT® TUNEL Alexa Fluor® 488 Imaging Assay kit (Thermofisher, UK) according to the manufacturer's instructions. Negative (vehicle only) and positive (DNase1) controls were also performed. The apoptotic index was determined by counting the percentage of positive cells from at least 400 nuclei from each biological replicate at 400x magnification.
[0106] Knockdown of ETV6 and FOXO1 genes Previous studies in invertebrate systems have identified Aop and Foxo genes, involved in ERK and AKT signaling, respectively, as determinants of lifespan in Drosophila melanogaster (Slack et al., 2015). The closest human homologs of these genes are FOXO1 (Kramer et al., 2003) and ETV6 / TEL (Jousset et al., 1997). We assessed the effect of knockdown of FOXO1 or ETV6 gene expression on cellular senescence and expression of splicing factors in late passage primary human fibroblasts. Late passage cells at PD=63 were plated at 6 × 10 per well in 6-well plates. 4Cells were seeded with 100 μg / ml of 1000 μl ... 4 Cells were seeded in three biological replicates and transfection was performed with 15 nM FOXO1, ETV6 siRNA or 15 nM control siRNA (Themofisher) for 48 h using Lipofectamine RNAiMAX reagent (Invitrogen, Paisley, UK). siRNA and morpholino sequences are given in Table 5.
[0107] Assessment of subcellular localization of FOXO1 and ETV6 Subcellular localization of ETV6 and FOXO1 proteins was assessed by immunofluorescence. Late passage primary human fibroblasts at PD=63 were plated in 24-well plates with three biological replicates at 1 × 10 per coverslip. 4Cells were seeded and grown for 10 days before assaying for subcellular localization. After treatment with 1 μM trametinib or SH-6, cells were fixed with 4% PFA for 10 min and permeabilized with PBS containing 0.025% Triton and 10% serum for 1 h. Anti-rabbit ETV6 (ab64909) and anti-rabbit FOXO1 (Abcam, UK) were added at dilutions of 1:1000 and 1:100, respectively, and samples were incubated overnight at 4 °C, then incubated with FITC-conjugated secondary goat anti-rabbit antibody (1:400) for 1 h, and nuclei were counterstained with DAPI. Coverslips were mounted on slides in DAKO fluorescent mounting medium (S3023; Dako, Santa Clara, USA). Nuclear localization was determined by counting the percentage of nuclear staining from at least 50 cells from each biological replicate under a Leica D4000 fluorescent microscope at 400× magnification.
[0108] Telomere length assessment 2 × 10 cells at PD=63 were plated in three biological replicates and then treated with either 1 μM of the ERK inhibitor trametinib or the AKT inhibitor SH-6 for 24 h. 5DNA was extracted from late passage primary human fibroblasts using the PureLink® Genomic DNA Mini Kit (Invitrogen™ / Thermo Fisher, MA, USA) according to the manufacturer's instructions. DNA quality and concentration were confirmed by Nanodrop spectrophotometry (NanoDrop / Thermo Fisher, MA, USA). Relative telomere length was determined using a modified qPCR protocol (O'Callaghan and Fenech, 2011). PCR reactions contained 1 μl EvaGreen (Solis Biodyne, Tartu, Estonia), 2 μM of each primer and 25 ng DNA in a total volume of 5 μl in a 384-well plate. Quantitative real-time polymerase chain reaction telomere assays were performed on a StepOne Plus with cycling conditions as follows: one cycle at 95° C. for 15 min, followed by 45 cycles of 95° C. for 10 s, 60° C. for 30 s, and 72° C. for 1 min. Mean relative telomere length was calculated as the ratio of telomeric repeat copy number to a single copy number gene (36B4) and normalized to the telomere length of untreated cells.
[0109] statistical analysis Unless otherwise stated, differences between treated and vehicle-only control cultures were assessed for statistical significance by two-way analysis of variance (ANOVA). Statistical analysis was performed using the computer-assisted Prism GraphPad program (Prism version 5.00, GraphPad Software, San Diego, CA).
[0110] Chromatin immunoprecipitation (ChIP) and gene set enrichment analysis The input data for this study were four publicly available human ChIP datasets for ETV6 and three datasets for FOXO1. The ETV6 datasets included two sets from K562 cells (GSE91511 and GSE95877) and two sets from GM12878 cells (GSE91904 and GSE96274). The FOXO1 datasets included datasets from human endometrial stromal cells (GSE69542), human pre-leukemic B cells (GSE80773) and normal human B cells (GSE68349). These datasets were imported into the Cistrome Project software (www.cistrome.org) and the identification of FOXO1 and ETV6 target genes was performed using the BETA (Binding and Expression Target Analysis) minus application with default parameters. The software detects transcription factor binding sites in the input data based on the controllability score after filtering peaks with a signal-to-background ratio less than 5-fold. GSEA pathway analysis was then performed using the Enrichr program using the 2016 reactome interface.
[0111] The above embodiments are not intended to limit the scope of protection afforded by the claims, but rather to illustrate examples of how the invention may be practiced.
[0112] References Anczukow O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, Muthuswamy SK, Krainer AR (2012). The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 19, 220-228. Arai T、Kano F、Murata M(2015). Translocation of forkhead box O1 to the nuclear periphery induces histone modifications that regulate transcriptional repression of PCK1 in HepG2 cells. Genes Cells. 20、340-357. Baar M、Brandt R、Putavet D、Klein J、Derks K、Bourgeois B、Stryeck S、Rijksen Y、van Willigenburg H、Feijtel D、van der pluijm I、Essers J、Van Cappellen Ivan J W、Houtsmuller AB、Pothof J、De Bruin RW、Madi T、Hoeijmakers JG、Campisi J、de Keizer P(2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell 169、133-147. Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, Saltness RA, Jeganathan KB, Verzosa GC, Pezeshki A, Khazaie K, Miller JD, Van Deursen J (2016). Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 530、184-189. Blaustein M、Pelisch F、Tanos T、Munoz MJ、Wengier D、Quadrana L、Sanford JR、Muschietti JP、Kornblihtt AR、Caceres JF、Coso OA、Srebrow A(2005). Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol. 12、1037-1044. Bullock N、Oltean S(2017). The many faces of SRPK1. J Pathol. 241、437-440. Chappell WH、Steelman LS、Long JM、Kempf RC、Abrams SL、Franklin RA、Basecke J、Stivala F、Donia M、Fagone P、Malaponte G、Mazzarino MC、Nicoletti F、Libra M、Maksimovic-Ivanic D、Mijatovic S、Montalto G、Cervello M、Laidler P、Milella M、Tafuri A、Bonati A、Evangelisti C、Cocco L、Martelli AM、McCubrey JA(2011). Ras / Raf / MEK / ERK and PI3K / PTEN / Akt / mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2、135-164. Cohen E、Dillin A(2008). The insulin paradox: aging, proteotoxicity and neurodegeneration. Nature reviews.Neuroscience. 9、759-767. Dansen TB、Burgering BM(2008). Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 18、421-429. de Magalhaes JP(2004). From cells to ageing: a review of models and mechanisms of cellular senescence and their impact on human ageing. Exp Cell Res. 300、1-10. Demidenko ZN、Shtutman M、Blagosklonny MV(2009). Pharmacologic inhibition of MEK and PI-3K converges on the mTOR / S6 pathway to decelerate cellular senescence. Cell cycle. 8、1896-1900. Deschenes M、Chabot B(2017). The emerging role of alternative splicing in senescence and aging. Aging Cell. Faragher RG、McArdle A、Willows A、Ostler EL(2017). Senescence in the aging process. F1000Res. 6、1219. Fontana L、Vinciguerra M、Longo VD(2012). Growth factors, nutrient signaling, and cardiovascular aging. Circ Res. 110、1139-1150. Fu XD、Ares M、Jr.(2014). Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev Genet. 15、689-701. Harries LW、Hernandez D、Henley W、Wood AR、Holly AC、Bradley-Smith RM、Yaghootkar H、Dutta A、Murray A、Frayling TM、Guralnik JM、Bandinelli S、Singleton A、Ferrucci L、Melzer D(2011). Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing. Aging Cell. 10、868-878. Heintz C、Doktor TK、Lanjuin A、Escoubas CC、Zhang Y、Weir HJ、Dutta S、Silva-Garcia CG、Bruun GH、Morantte I、Hoxhaj G、Manning BD、Andresen BS、Mair WB(2016). Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in C. elegans. Nature. 541、102-106. Hock H、Shimamura A(2017). ETV6 in hematopoiesis and leukemia predisposition. Semin Hematol. 54、98-104. Holly AC、Melzer D、Pilling LC、Fellows AC、Tanaka T、Ferrucci L、Harries LW(2013). Changes in splicing factor expression are associated with advancing age in man. Mechanisms of ageing and development. 134、356-366. Jousset C、Carron C、Boureux A、Quang CT、Oury C、Dusanter-Fourt I、Charon M、Levin J、Bernard O、Ghysdael J(1997). A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J. 16、69-82. Kajita K、Kuwano Y、Kitamura N、Satake Y、Nishida K、Kurokawa K、Akaike Y、Honda M、Masuda K、Rokutan K(2013). Ets1 and heat shock factor 1 regulate transcription of the Transformer 2beta gene in human colon cancer cells. J Gastroenterol. 48、1222-1233. Kang X、Chen W、Kim RH、Kang MK、Park NH(2009). Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells. Oncogene. 28、565-574. Kourtis N、Tavernarakis N(2011). Cellular stress response pathways and ageing: intricate molecular relationships. EMBO J. 30、2520-2531. Kramer JM、Davidge JT、Lockyer JM、Staveley BE(2003). Expression of Drosophila FOXO regulates growth and can phenocopy starvation. BMC Dev Biol. 3、5. Krech T、Thiede M、Hilgenberg E、Schafer R、Jurchott K(2010). Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signaling pathway perturbations. BMC Cancer. 10、287. Lareau LF、Brenner SE(2015). Regulation of splicing factors by alternative splicing and NMD is conserved between kingdoms yet evolutionarily flexible. Mol Biol Evol. 32、1072-1079. Latorre E、Birar VC、Sheerin AN、Jeynes JCC、Hooper A、Dawe HR、Melzer D、Cox LS、Faragher RGA、Ostler EL、Harries LW(2017). Small molecule modulation of splicing factor expression is associated with rescue from cellular senescence. BMC Cell Biol. 18、31. Latorre E、Harries LW(2017). Splicing regulatory factors, ageing and age-related disease. Ageing Res Rev. 36、165-170. Lee BP、Pilling LC、Emond F、Flurkey K、Harrison DE、Yuan R、Peters LL、Kuschel G、Ferrucci L、Melzer D、Harries LW(2016). Changes in the expression of splicing factor transcripts and variations in alternative splicing are associated with lifespan in mice and humans. Aging Cell. 15、903-913. Lin G、Tang Z、Ye YB、Chen Q(2012). NF-kappaB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IkappaBalpha pathway. Oncol Rep. 27、1527-1534. Lin X、Yan J、Tang D(2013). ERK kinases modulate the activation of PI3 kinase related kinases (PIKKs) in DNA damage response. Histol Histopathol. 28、1547-1554. O’Callaghan NJ、Fenech M(2011). A quantitative PCR method for measuring absolute telomere length. Biol Proced Online. 13、3. Pardo R、Andreolotti AG、Ramos B、Picatoste F、Claro E(2003). Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms. J Neurochem. 87、417-426. Pise-Masison CA、Radonovich M、Sakaguchi K、Appella E、Brady JN(1998). Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J Virol. 72、6348-6355. Rasighaemi P、Ward AC(2017). ETV6 and ETV7: Siblings in hematopoiesis and its disruption in disease. Crit Rev Oncol Hematol. 116、106-115. Rhim JH、Luo X、Gao D、Xu X、Zhou T、Li F、Wang P、Wong ST、Xia X(2016). Cell type-dependent Erk-Akt pathway crosstalk regulates the proliferation of fetal neural progenitor cells. Sci Rep. 6、26547. Salama R、Sadaie M、Hoare M、Narita M(2014). Cellular senescence and its effector programs. Genes Dev. 28、99-114. Salih DA、Brunet A(2008). FoxO transcription factors in the maintenance of cellular homeostasis during aging. Current opinion in cell biology. 20、126-136. Salminen A、Kauppinen A、Kaarniranta K(2012). Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal. 24、835-845. Shin C、Manley JL(2004). Cell signalling and the control of pre-mRNA splicing. Nat Rev Mol Cell Biol. 5、727-738. Slack C、Alic N、Foley A、Cabecinha M、Hoddinott MP、Partridge L(2015). The Ras-Erk-ETS-Signaling Pathway Is a Drug Target for Longevity. Cell. 162、72-83. Suh Y、Atzmon G、Cho MO、Hwang D、Liu B、Leahy DJ、Barzilai N、Cohen P(2008). Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proceedings of the National Academy of Sciences of the United States of America. 105、3438-3442. Tarn WY(2007). Cellular signals modulate alternative splicing. J Biomed Sci. 14、517-522. van Deursen JM(2014). The role of senescent cells in ageing. Nature. 509、439-446. van Heemst D、Beekman M、Mooijaart SP、Heijmans BT、Brandt BW、Zwaan BJ、Slagboom PE、Westendorp RG(2005). Reduced insulin / IGF-1 signalling and human longevity. Aging Cell. 4、79-85. Wang Q、Chen X、Hay N(2017). Akt as a target for cancer therapy: more is not always better (lessons from studies in mice). Br J Cancer. 117、159-163. Webb AE、Kundaje A、Brunet A(2016). Characterization of the direct targets of FOXO transcription facors throughout evolution. Aging Cell. 15、673-685.
Claims
1. A composition comprising one or more intermediate non-coding RNA regulators that regulate the expression of ETV6 for use in the prevention, management, amelioration or treatment of an age-related disease or condition or cancer.
2. The composition of claim 1, wherein the age-related disease or condition or cancer comprises dysregulation of expression of splicing factors and / or dysregulation of cellular senescence.
3. A composition comprising one or more intermediate non-coding RNA regulators that regulate FOXO1 expression for use in the prevention, management, amelioration or treatment of an age-related disease or condition or cancer, wherein the age-related disease or condition or cancer involves dysregulation of splicing factor expression and / or dysregulation of cellular senescence.
4. 4. The composition of any one of claims 1 to 3, wherein the age-related disease or condition is selected from Alzheimer's disease, cardiovascular disease, hypertension, osteoporosis, type 2 diabetes, cancer, Parkinson's disease, cognitive impairment, frailty or progeroid syndrome.
5. The composition of any one of claims 1 to 4, wherein the composition comprises two or more of the intermediate non-coding RNA regulatory factors.
6. The composition of any one of claims 1 to 5, wherein the intermediate non-coding RNA regulatory factor comprises a miRNA, a miRNA mimic or an antagomir.
7. The composition of claim 6, wherein the intermediate non-coding RNA regulatory factor comprises two or more miRNAs, miRNA mimics or antagomirs capable of binding to two or more different complementary antisense miRNA sequences.
8. The composition of any one of claims 5 to 7, wherein the intermediate non-coding RNA regulatory factor is selected from one or more of the following: MIR142; MIR3124; MIR3188; MIR3196; MIR320E; MIR330; MIR3675; MIR4316; MIR4488; MIR4496; MIR4513; MIR4674; MIR4707; MIR4772; MIR6088; MIR6129; MIR6780A; MIR6797; MIR6803; MIR6810; MIR6842; or MIR7155.
9. 9. The composition of claim 8, wherein the intermediate non-coding RNA regulatory factor is selected from one or more of the following: MIR3124; MIR3675; MIR4496; MIR6780A; MIR6810; MIR6842; or MIR7155.
10. A method for increasing expression of a splicing factor, reducing cellular senescence, and / or promoting re-entry into the cell cycle in a cell culture, comprising administering to the cell culture a composition comprising an intermediate non-coding RNA regulatory factor that regulates expression of FOXO1 and / or ETV6.
11. The method of claim 8 , wherein the composition comprises two or more of the intermediate non-coding RNA regulatory factors.
12. The method of claim 8 or claim 9, wherein the intermediate non-coding RNA regulatory factor comprises a miRNA, a miRNA mimic or an antagomir.
13. The method of any one of claims 8 to 10, wherein the FOXO1 and / or ETV6 expression regulator comprises two or more miRNAs, miRNA mimics or antagomirs capable of binding to two or more different complementary antisense miRNA sequences.
14. Use of a composition comprising one or more intermediate non-coding RNA regulators that regulate the expression of ETV6 for the cosmetic treatment of the effects of aging.
15. The use according to claim 14, wherein the effects of aging include dysregulation of expression of splicing factors and / or dysregulation of cellular senescence.
16. Use of a composition comprising one or more intermediate non-coding RNA regulators that regulate the expression of FOXO1 for the cosmetic treatment of the effects of aging, said effects of aging comprising dysregulation of expression of splicing factors and / or dysregulation of cellular senescence.
17. The use according to any one of claims 14 to 16, wherein the composition comprises two or more of said intermediate non-coding RNA regulatory factors.
18. 18. The use according to any one of claims 14 to 17, wherein the intermediate non-coding RNA regulatory factor comprises a miRNA, a miRNA mimic or an antagomir.
19. The use of claim 18, wherein the FOXO1 or ETV6 expression regulator comprises two or more miRNAs, miRNA mimics or antagomirs capable of binding to two or more different complementary antisense miRNA sequences.
20. The use of any one of claims 14 to 19, wherein the intermediate non-coding RNA regulatory factor is selected from one or more of the following: MIR142; MIR3124; MIR3188; MIR3196; MIR320E; MIR330; MIR3675; MIR4316; MIR4488; MIR4496; MIR4513; MIR4674; MIR4707; MIR4772; MIR6088; MIR6129; MIR6780A; MIR6797; MIR6803; MIR6810; MIR6842; or MIR7155.
21. 21. The use of claim 20, wherein the intermediate non-coding RNA regulatory factor is selected from one or more of the following: MIR3124; MIR3675; MIR4496; MIR6780A; MIR6810; MIR6842; or MIR7155.
22. Use of a composition comprising one or more intermediate non-coding RNA regulatory factors that regulate expression of FOXO1 and / or ETV6 as a research tool for restoring and / or increasing expression of splicing factors, or for reducing or reversing cellular senescence and / or re-entry into the cell cycle.
23. Use of a composition comprising one or more intermediate non-coding RNA regulatory factors that regulate the expression of FOXO1 and / or ETV6 for cell culture.
24. 24. The use according to claim 23, wherein the composition is for increasing the number of viable passages in cell culture and / or for reducing the senescent cell population.
